导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.78% | 2198/4773 |
| 近一周 | -0.56% | 1137/5465 |
| 近一月 | 2.13% | 246/5421 |
| 近一季 | 3.74% | 429/5231 |
| 近半年 | -3.77% | 2594/4920 |
| 近一年 | 0.31% | 2717/4394 |
| 近两年 | 15.97% | 2720/2954 |
| 近三年 | 19.47% | 1506/2253 |
| 成立以来 | 58.36% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.84% 847/4961 |
-10.95% 4206/5312 |
- - |
- - |
| 2025 | -2.35% 3337/4813 |
-2.67% 2949/3635 |
2.94% 1250/4076 |
-4.05% 4018/4524 |
1.59% 1312/4813 |
| 2024 | 24.98% 274/3463 |
8.66% 174/2808 |
4.17% 231/3014 |
9.61% 2684/3129 |
0.74% 1174/3463 |
| 2023 | 12.75% 55/2656 |
7.03% 612/2280 |
5.38% 68/2385 |
3.05% 205/2515 |
-3.00% 571/2655 |
| 2022 | -2.44% 58/2207 |
0.04% 118/1919 |
-1.14% 1679/2016 |
-5.37% 73/2113 |
4.25% 571/2208 |
| 2021 | 8.55% 472/1822 |
6.79% 89/1255 |
-2.95% 1232/1330 |
4.71% 325/1466 |
0.03% 1175/1822 |
| 2020 | 2.22% 922/1250 |
-10.15% 761/1028 |
0.77% 998/1067 |
9.71% 631/1164 |
2.92% 956/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 嘉实沪深300红利低波动ETF联接C VS. 长安沪深300非周期A(740101) |